John L. (@meeomhealthclub) 's Twitter Profile
John L.

@meeomhealthclub

R&D @ MEEOM® the Fastest Growing #PrecisionMedicine #Charity that Cures #Cancer #Stroke #ADHD #ASD #CD #COPD #HBV #HCV #FLD #OSA @UofT Alum

ID: 1616490431251873811

linkhttp://www.meeomhealth.club calendar_today20-01-2023 17:39:53

7,7K Tweet

3,3K Followers

5,5K Following

Yale School of Medicine (@yalemed) 's Twitter Profile Photo

YSM immunobiologist @virusesimmunity has been named to both the #TIME100 and TIME100 Health, two of TIME’s lists of the most influential people of 2024. The honor recognizes her pioneering #research into post-acute #infection syndromes like #longCOVID. brnw.ch/21wJrnp

YSM immunobiologist @virusesimmunity has been named to both the #TIME100 and TIME100 Health, two of <a href="/TIME/">TIME</a>’s lists of the most influential people of 2024. The honor recognizes her pioneering #research into post-acute #infection syndromes like #longCOVID.
 brnw.ch/21wJrnp
Yale School of Medicine (@yalemed) 's Twitter Profile Photo

“A game changer in #brain tumor treatment:” With a Yale Ventures grant, a team of Yale Department of Orthopaedics and Rehabilitation researchers will create an #AI-based approach to modeling vestibular schwannoma (VS) #tumors in #3D. medicine.yale.edu/ortho/news-art…

“A game changer in #brain tumor treatment:” With a <a href="/Yale_Ventures/">Yale Ventures</a> grant, a team of <a href="/OrthoAtYale/">Yale Department of Orthopaedics and Rehabilitation</a> researchers will create an #AI-based approach to modeling vestibular schwannoma (VS) #tumors in #3D.
medicine.yale.edu/ortho/news-art…
Francisco Martínez (@franmartinezgr) 's Twitter Profile Photo

SpliceVarDB: A comprehensive database of experimentally validated human splicing variants #RareDisease #Genetics #splicing cell.com/ajhg/fulltext/…

SpliceVarDB: A comprehensive database of experimentally validated human splicing variants #RareDisease #Genetics #splicing cell.com/ajhg/fulltext/…
Gamze Gürsoy (@gamzeandgursoy) 's Twitter Profile Photo

Super excited to announce our new framework to store, integrate, and analyze genetic and clinical data under a secure framework by leveraging blockchain technology : nature.com/articles/s4159… lead by brilliant student Ahmed Elhussein Columbia DBMI (1/n)

Jennifer Trowbridge (@trowbridgelab) 's Twitter Profile Photo

There are few words expressing my joy, awe & admiration for this group. They have solved a 20+ year-long, seemingly impossible challenge: generating transplantable hematopoietic stem cells from human pluripotent cells. Just... WOW. nature.com/articles/s4158… 🤩 AndrewElefanty

Colinda Scheele (@colindascheele) 's Twitter Profile Photo

Super happy to share that our paper is published in nature today! We've discovered how the breast is protected against tumor initiation—though it comes at a cost. 📰Read all about it here: bit.ly/3MSxoa1 🏥CCB_VIB_KUL Department of Oncology - KU Leuven The Netherlands Cancer Institute Van Rheenen Lab Benjamin Simons

Joe Grove (@grovelab) 's Twitter Profile Photo

A viral family tree gets a makeover! 🧬🦠🔍Our new study, out today in nature, reveals the Flaviviridae's hidden history. MRC-Uni of Glasgow Centre for Virus Research #virology nature.com/articles/s4158…

The Cancer Letter (@thecancerletter) 's Twitter Profile Photo

As NCI’s appropriations stay flat, Rathmell (Dr. Kimryn Rathmell) keeps the FY26 bypass budget steady at just under $11.5B. cancerletter.com/nci-director-r…

Gustavo Monasterio O. (@gamonasterioo) 's Twitter Profile Photo

A beautiful and elegant answer to a long-standing mystery: Why do we itch? γδ T cell, IL-3, and sensory neurons! A γδ T cell–IL-3 axis controls allergic responses through sensory neurons | Nature nature.com/articles/s4158…

Cancer Cell (@cancer_cell) 's Twitter Profile Photo

Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells dlvr.it/TD4Lzj

Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells dlvr.it/TD4Lzj
Erika Ruiz-Garcia (@betzabe100) 's Twitter Profile Photo

Incredible experience contributing to the creation and development of the ASCO 2025 Annual Meeting Program. The dedication of the volunteers, ASCO President, Educational and Scientific Program Chairs: Robin Zon Cardinale B. Smith Erika Hamilton, MD and ASCO staff's support is priceless

Incredible experience contributing to the creation and development of the ASCO 2025 Annual Meeting Program. The dedication of the volunteers, ASCO President, Educational and Scientific Program Chairs: Robin Zon <a href="/cardismith/">Cardinale B. Smith</a> <a href="/ErikaHamilton9/">Erika Hamilton, MD</a> and <a href="/ASCO/">ASCO</a> staff's support is priceless
Robin Zon, MD, FACP, FASCO (@ascopres) 's Twitter Profile Photo

Incredible day ASCO HQ w Dr. Cardinale B. Smith leading as #ASCO25 Education Chair. Thank you to Cardi & the track leaders for your thoughtfulness, intentionality and leadership in helping Drive Knowledge to Action! Next up: #ASCO25 science under the leadership of Dr. Erika Hamilton, MD!

Incredible day <a href="/ASCO/">ASCO</a> HQ w Dr. <a href="/cardismith/">Cardinale B. Smith</a> leading as #ASCO25 Education Chair. Thank you to Cardi &amp; the track leaders for your thoughtfulness, intentionality and leadership in helping Drive Knowledge to Action!

Next up: #ASCO25 science under the leadership of Dr. <a href="/ErikaHamilton9/">Erika Hamilton, MD</a>!
Robin Zon, MD, FACP, FASCO (@ascopres) 's Twitter Profile Photo

So thrilled to be at #ESMO24—my first ESMO! Stopped by the ASCO booth just in time to meet this NEW ASCO member from Sri Lanka. Welcome! I hope to see many of you while here!

So thrilled to be at #ESMO24—my first ESMO! Stopped by the ASCO booth just in time to meet this NEW <a href="/ASCO/">ASCO</a> member from Sri Lanka. Welcome! I hope to see many of you while here!
Bárbara Melão, MD (@bavilima) 's Twitter Profile Photo

PEACE-3 at #ESMO24 Practice changing for 1L mCRPC patients who didn’t use ARPI in mCSPC ➡️1L mCRPC patients with bone metastases ➡️1:1 to ENZ vs ENZ-RAD (6 cycles) ➡️Primary endpoint: rPFS ➡️446 men, FU 42.2 months ➡️HR for rPFS 0.69 (p=0.0009) ➡️HR for OS 0.69 (p=0.0031)

PEACE-3 at #ESMO24
Practice changing for 1L mCRPC patients who didn’t use ARPI in mCSPC

➡️1L mCRPC patients with bone metastases 
➡️1:1 to ENZ vs ENZ-RAD (6 cycles)
➡️Primary endpoint: rPFS
➡️446 men, FU 42.2 months
➡️HR for rPFS 0.69 (p=0.0009)
➡️HR for OS 0.69 (p=0.0031)